Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848976 | 0.98 | MAPT (0.46) | DRD2DRD4DRD3MAPTHTR1A | |
| SCHEMBL2852888 | 0.94 | MAPT (0.48) | MAPTHTR1ASIRT6LMNAKMT2A | |
| SCHEMBL2192247 | 0.85 | ALDH1A1 (0.46) | DRD2DRD4DRD3MAPTHTR1A | |
| SCHEMBL2197706 | 0.85 | KDM4E (0.48) | DRD2DRD4DRD3HTR1ALMNA | |
| SCHEMBL2195337 | 0.85 | SLC6A2 (0.43) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL2194931 | 0.85 | KDM4E (0.47) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL3424068 | 0.84 | KDM4E (0.49) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL3258946 | 0.83 | KDM4E (0.47) | DRD2DRD4DRD3HTR1ALMNA | |
| SCHEMBL2191495 | 0.83 | ALDH1A1 (0.46) | DRD2DRD4DRD3MAPTHTR1A | |
| SCHEMBL2197948 | 0.83 | KDM4E (0.50) | DRD2DRD4DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598180-B2 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1715921-B1 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | ABRAXIS BIOSCIENCE, INC. | 2010-12-02 | — | — | US | disclosed |
| US-7795266-B2 | Tetrahydroindolone derivatives for treament of neurological conditions | ABRAXIS BIOSCIENCE, INC. | 2010-09-14 | — | — | US | disclosed |
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | TPH2, TPH1, GRIK5 | DRD2 646/4885DRD4 681/4885DRD3 599/4885 |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | NLN, CYP11B2, GRIN2C | DRD2 464/4885DRD4 616/4885DRD3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.